Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You might want to check this uranium out RSC-V
You might want to check this one RSC-V
ONC-T NR today 36m at 5.52
Oncolytics receives U.S. patent 7,014,847
2006-03-27 06:41 ET - News Release
Dr. Matt Coffey reports
ONCOLYTICS BIOTECH INC. ANNOUNCES ISSUANCE OF 15TH U.S. PATENT
Oncolytics Biotech Inc. has been granted United States patent 7,014,847, entitled, "Methods for Preventing Reovirus Recognition for the Treatment of Cellular Proliferative Disorders." The claims describe methods for preventing reovirus recognition by the host immune system, while concurrently or subsequently administering reovirus, resulting in substantial lysis of the proliferating cells.
"The claims in this United States patent allow manipulation of the immune system that may enhance the effectiveness of Reolysin treatment," said Dr. Matt Coffey, chief scientific officer of Oncolytics. "The use of immune modulation with this class of biologic agent is a growing and promising field of research and we are pleased to have secured patent protection for this new treatment modality."
We seek Safe Harbor.
SSB-T NR today 83m at .62
Glacier buys GVIC Publications for $9.25-million
2006-03-24 15:42 ET - News Release
See News Release (C-GVC) Glacier Ventures International Corp
Mr. Jonathon Kennedy reports
GLACIER ANNOUNCES EQUITY INVESTMENT IN GVIC PUBLICATIONS LTD.
Glacier Ventures International Corp.'s wholly owned subsidiary, 0747036 B.C. Ltd., has acquired approximately 94.9 per cent of the equity of GVIC Publications Ltd. (formerly Stressgen Biotechnologies Corp.)
Under the transaction, GVIC Publications received shareholder and regulatory approval to be restructured under a plan of arrangement whereby:
all of GVIC Publication's assets and liabilities were transferred to a new biopharmaceutical company that will carry on the former business carried on by Stressgen Biotechnologies; and
0747036 acquired 5,838,284 Class B voting shares and 237,178,557 Class C non-voting of GVIC Publications, representing approximately 40 per cent of the Class B voting shares, 98.19 per cent of the Class C non-voting shares and 94.9 per cent of the equity in GVIC Publications for $9.25-million.
0747036 and Glacier have no interest in the new biopharmaceutical company.
GVIC Publications will now focus on acquiring one or more businesses operating in the information communications sectors. GVIC Publications will seek to raise capital as required to finance such acquisitions.
Glacier acquired the shares of GVIC Publications for investment purposes.
We seek Safe Harbor.
Did you see this post?
http://www.investorshub.com/boards/read_msg.asp?message_id=10307406
NRI-T Sedar today 133m at .475
Way to go. I am watching the chart may get some later when it settles down again.
OTG
Quite the correction today but IMHO that will change to the upside. Also check out RBM-V it is interesting as well. Happy trading.
OTG
SSB-T NR today Sedar plus (see below) 83m at .63
Stressgen loses $19.6-million in 2005
2006-03-22 09:26 ET - News Release
Mr. Gregory McKee reports
STRESSGEN BIOTECHNOLOGIES ANNOUNCES 2005 FINANCIAL RESULTS
Stressgen Biotechnologies Corp. has provided financial results for the year ended Dec. 31, 2005.
For the year ended Dec. 31, 2005, the company reported a net loss from continuing operations of $27.1-million, or 37 cents (31 U.S. cents) per share, compared with a net loss from continuing operations of $31.8-million, or 44 cents (34 U.S. cents) per share for the year ended Dec. 31, 2004. The company had cash and short-term investments of $4.4-million at Dec. 31, 2005. In January, 2006, the company entered into an agreement to reorganize and receive up to $9.25-million in non-dilutive financing.
Stressgen highlights
Corporate and finance:
appointed Gregory M. McKee as the new president, chief executive officer and director;
received approximately $8.72-million from sale of bioreagent business;
implemented two restructurings to focus corporate resources on the advancement of HspE7, lowering burn rate and decreasing operational overhead;
completed equity financings totalling gross proceeds of $3.6-million; and
entered into an agreement to reorganize and receive up to $9.25-million in non-dilutive funding.
Clinical:
showed higher than expected complete responses with HspE7 among women with high-grade cervical dysplasia.
Intellectual property:
granted United States patent covering therapeutic products to treat hepatitis B virus;
granted U.S. patent covering new methods of manufacturing HspE7; and
defeated Antigenics' challenge to European patent, a decision that has been subsequently appealed by Antigenics.
Manufacturing:
completed manufacture of commercial grade HspE7.
"We have made substantial progress in re-invigorating the company in 2005," commented Mr. McKee. "All of the milestones completed in 2005 have strengthened the foundation to support the continued development of HspE7 for human papillomavirus- (HPV) related indications."
CONSOLIDATED STATEMENT OF OPERATIONS
Year ended Dec. 31
(In thousands of dollars)
2005 2004
Revenue
Collaborative
R&D revenue $ 645 $ 700
Operating expenses
Research and
development 20,766 25,913
Selling, general
and admin 5,891 6,247
Restructuring 1,370 -
------- -------
28,027 32,160
------- -------
Operating loss (27,382) (31,460)
------- -------
Other income
(expenses)
Interest income 1,092 777
Net foreign
exchange (loss) (560) (938)
Interest (expense) (37) (96)
------- -------
495 (257)
------- -------
Net (loss) from
continuing
operations before
tax expense (26,887) (31,717)
Income tax
expense, net (187) (128)
------- -------
Net (loss) from
continuing
operations (27,074) (31,845)
Net income from
discontinued
operations 7,460 1,580
------- -------
Net (loss) $(19,614) $(30,265)
======= =======
Basic and diluted
(loss) per
common share
From continuing
operations $ (0.37) $ (0.44)
From discontinued
operations 0.10 0.02
------- -------
$ (0.27) $ (0.42)
We seek Safe Harbor.
APT NR today close 3.04
Alpha Pro Tech, Ltd. Announces 25% Increase in Revenue and 33% Increase in Net Income for Fiscal 2005
2006-03-22 16:00 ET - News Release
NOGALES, Ariz. -- (Business Wire) -- March 22, 2006
Alpha Pro Tech (AMEX:APT) (CHX:APT), a leading
manufacturer of disposable protective apparel and building products,
announced its financial results for the fourth quarter and full-year
period ended December 31, 2005.
Revenues for the three months ended December 31, 2005 increased
9.4% to $7.0 million compared to $6.4 million in the fourth quarter of
2004. New sales of construction supply weatherization products,
including the Engineered Products segment's building wrap and roof
underlayment, totaled $1.2 million for the quarter. Sales for the
Disposable Protective Apparel segment for the quarter were $3.7
million, a 21.1% decrease compared to the $4.7 million reported for
the same period of 2004 as the Company experienced decreased orders
primarily from its largest distributor due to a slowdown in orders
from them to reduce their inventory levels. Although shipments to them
declined in the fourth quarter of 2005, sales to the distributor's end
users remained fairly consistent with prior quarters. Infection
Control segment sales for the fourth quarter increased by 33.4% to
$1.6 million compared to the fourth quarter of last year, which
benefited from increased awareness surrounding Avian Flu. Mask sales
in the fourth quarter were up 36% as compared to the average for the
first three quarters of 2005. Extended care products were relatively
unchanged at $573,000 for the fourth quarter as the Company
experienced similar levels of demand for the Company's Extended Care
Unreal Lambskin products.
Gross profit decreased by 1.0 % to $3.1 million, and represented
44.3% of sales for the fourth quarter of 2005 as compared to a gross
profit of $3.1 million, which represented 48.9% of sales, for the same
period in 2004. The decrease in overall gross margins was directly
related to the contribution of Engineered Products revenue, which
carries lower overall margins than the Company's other segments and
initial manufacturing startup costs in this segment. Excluding
Engineered Products, gross profit margin was 51.7% for the fourth
quarter of 2005, up from gross profit margin of 48.9% for fiscal 2004.
Gross profit in the Engineered Products segment was 25.1% for the
fourth quarter, as compared to 28.2% for the third quarter and 25.2%
for the second quarter of 2005. Gross profit on this product line is
expected to increase to the low to mid 30% range by the second half of
2006 as the Company generates increased sales in this segment and the
joint venture in India becomes fully operational.
Selling, general and administrative expenses increased by 13.2% to
$2.5 million, or 35.7% of sales, for the quarter from $2.2 million, or
34.5% of sales for the quarter ended December 31, 2004. This was
primarily the result of increased Engineered Products expenses,
increased rent and utilities expense, increased travel expenses and
increased factory indirect expenses. Management believes it has the
necessary infrastructure required to substantially grow revenue and
accordingly expects operating expenses to remain fairly stable for the
coming twelve months, despite planned revenue growth.
Income from operations decreased by 40.3% to $478,000 for the
quarter compared to income from operations of $801,000 for the fourth
quarter last year. The decrease was due to a shift in product mix,
which included a higher contribution from our lower-margin engineered
products and a reduction in sales in our core apparel business. Net
income for the fourth quarter was $309,000, or $0.01 per fully diluted
share, compared to net income of $556,000, or $0.02 per fully diluted
share for the quarter ended December 31, 2004.
In 2006 the Company will introduce two new apparel product lines
targeted to the industrial and clean room marketplace. Comfortech(TM),
the first product, has been under development for two years and is a
new technically superior and lower cost line of non-breathable
material used in coveralls, gowns, lab coats and other apparel
products for the pharmaceutical, medical device and lab animal
research markets. The second is the Comfortech Certified(TM) product
line which is targeted for manufacturing facilities and other
applications where reducing bio-contamination is a priority. The
Company has received beta orders for the Comfortech(TM) product during
the first quarter of 2006 and expects to receive initial orders during
the second quarter of 2006. Based on initial customer indications,
management expects both of these products to begin to contribute more
meaningfully to revenue during the second half of 2006.
Al Millar, President of Alpha Pro Tech commented, "We continued to
grow our top line while maintaining the appropriate operating expense
controls to deliver profitable results. During the fourth quarter we
witnessed a decline in orders from our largest apparel distributor,
however, sales to their end users remained fairly consistent with
prior quarters. Based on initial indications, we anticipate this
distributor will return to more normalized ordering patterns in the
latter part of the first quarter of 2006."
For the year ended December 31, 2005, sales increased 25.2% or
$6.3 million to $31.1 million from $24.8 million reported for 2004.
The increase was due primarily to $4.7 million in incremental sales
from Engineered Products, specifically construction supply
weatherization products which was a new segment in 2005 and a $1.7
million or 9.3% increase in sales of Disposable Protective Apparel.
Infection Control segment sales for the year were flat year-over-year
at $5.1 million. Discounting the $600,000 one-time sale of N-95 masks
during the second quarter of 2004, sales in this segment would have
increased approximately 14% on a comparable basis. Extended Care
products decreased by 6.7% or $0.1 million to $1.8 million as the
Company experienced softness in the sale of medical bed pads. This
segment is not expected to be a growth area for the Company.
Gross profit margin decreased to 45.5% for the year from 49.5% for
the same period in 2004. Excluding Engineered Products, gross profit
margin was 49.1% for the year ended December 31, 2005 compared to
49.5% for the same period of 2004, in line with the Company's gross
profit margin for 2004.
Selling, general and administrative expenses increased by 9.8% to
$9.8 million for the year, representing 31.5% of sales, compared to
$8.9 million, or 35.9% of sales, for the year ended December 31, 2004.
The increase in absolute dollars was primarily related to increased
expenses of $802,000 for the Engineered Products segment.
Depreciation and amortization expense decreased by 3.5% to
$499,000 for the year ended December 31, 2005 from $517,000 for the
same period in 2004.
Income from operations increased by 35.4% to $3.9 million for the
year from $2.8 million last year due primarily to an increase in gross
profit of $1.9 million partially offset by an increase in selling,
general and administrative expenses of $0.9 million. Net income for
the year ended December 31, 2005 was up 32.6% to $2.5 million, or
$0.10 per fully diluted share (based on 25.2 million fully diluted
shares) compared to net income of $1.8 million, or $0.08 per fully
diluted shares (based on 24.6 million fully diluted shares) for fiscal
2004.
The balance sheet continues to remain strong with a current ratio
of 6.51 to 1 as of December 31, 2005. Additionally at year end, the
company reported no long-term debt, and shareholders' equity improved
to $18.6 million from $15.7 million on December 31, 2004. As of
December 31, 2005, the Company had cash and cash equivalents of $1.2
million and working capital of $14.2 million. The Company's cash
position increased by $0.9 million from the third quarter, primarily
related to a reduction in accounts receivable. The Company has a $3.5
million dollar line of credit of which almost all is still available.
"We see significant growth opportunities for both our core
Disposable Protective Apparel business in addition to our Engineered
Products Division as we further penetrate each market respectively
with new and innovative products," Mr. Millar continued. "Our Miami
Dade Certification received in October 2005 validates the integrity of
our Engineered Products offering and helps to clear the way for Perma
R to increase sales in the geographic areas where their customers are
located. Additionally, the Comfortech(TM) line of products should
bolster our Disposable Protective Apparel sales in 2006 as we look to
capture incremental market share."
About Alpha Pro Tech, Ltd.
Alpha Pro Tech develops, manufactures and markets innovative
disposable and limited-use protective apparel products for the
industrial, clean room, medical and dental markets. In addition, Alpha
ProTech Engineered Products, Inc. manufactures and markets a line of
construction weatherization products, including building wrap, roof
underlayment and mold resistant framing sealant. The Company has
manufacturing facilities in Salt Lake City, Utah; Nogales, Arizona;
Janesville, Wisconsin; and Valdosta, Georgia. For more information and
copies of all news releases and financials, visit Alpha Pro Tech's
Website at http://www.alphaprotech.com.
The Private Securities Litigation Reform Act of 1995 ("Act")
provides a safe harbor for forward-looking information made on behalf
of the Company. Forward-looking statements involve risks,
uncertainties and assumptions as described from time to time in
registration statements, annual reports and other periodic reports and
filings of the Company filed with the Securities and Exchange
Commission. All statements, other than statements of historical facts
which address the Company's expectations of sources of capital or
which express the Company's expectations for the future with respect
to financial performance or operating strategies, can be identified as
forward-looking statements. As a result, there can be no assurance
that the Company's future results will not be materially different
from those described herein as "believed," "anticipated," "estimated"
or "expected," which reflect the current views of the Company with
respect to future events. We caution readers that these
forward-looking statements speak only as the date hereof. The Company
hereby expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements to reflect
any change in the Company's expectations or any change in events,
conditions or circumstances on which such statement is based.
-0-
*T
Alpha ProTech, Ltd.
Consolidated Statement of Operations
For the Three Months Ended For the Year Ended
December 31, December 31,
(unaudited)
2005 2004 2005 2004
Sales $ 7,017,000 $ 6,413,000 $31,095,000 $24,841,000
Cost of goods sold,
excluding
depreciation and
amortization 3,908,000 3,274,000 16,948,000 12,555,000
----------- ------------ ----------- -----------
Gross margin 3,109,000 3,139,000 14,147,000 12,286,000
Expenses:
Selling, general
and
administrative 2,507,000 2,214,000 9,796,000 8,925,000
Depreciation and
amortization 124,000 124,000 499,000 517,000
----------- ------------ ----------- -----------
Income from
operations 478,000 801,000 3,852,000 2,844,000
Other income
(expense)
Equity in income
(loss) of
unconsolidated
affiliates (16,000) - (16,000) -
Gain on sale
of assets - - - 7,000
Interest,
net - 11,000 24,000 7,000
----------- ------------ ----------- -----------
Income before
provision for
income taxes 462,000 812,000 3,860,000 2,858,000
Provision for
income taxes 153,000 256,000 1,410,000 1,011,000
----------- ------------ ----------- -----------
Net income $ 309,000 $ 556,000 $ 2,450,000 $ 1,847,000
=========== ============ =========== ===========
Basic net income
per share $ 0.01 $ 0.02 $ 0.10 $ 0.08
=========== ============ =========== ===========
Diluted net income
per share $ 0.01 $ 0.02 $ 0.10 $ 0.08
=========== ============ =========== ===========
Basic weighted
average shares
outstanding 23,731,350 23,435,038 23,684,229 23,215,809
=========== ============ =========== ===========
Diluted weighted
average shares
outstanding 25,522,533 24,608,146 25,247,236 24,624,613
=========== ============ =========== ===========
BALANCE SHEET HIGHLIGHTS
December 31st December 31st
2005 2004
Cash $ 1,163,000 $ 4,875,000
Total Current Assets $ 16,761,000 $ 15,348,000
Net Property and Equipment $ 3,389,000 $ 3,256,000
Total Assets $ 21,871,000 $ 18,789,000
Total Current Liabilities $ 2,576,000 $ 2,437,000
Total Liabilities $ 3,228,000 $ 3,089,000
Shareholder's Equity $ 18,643,000 $ 15,700,000
Total Liabilities and Equity $ 21,871,000 $ 18,789,000
*T
Contacts:
Alpha Pro Tech, Ltd.
Al Millar or Donna Millar, 905-479-0654
e-mail: ir@alphaprotech.com
or
Hayden Communications, Inc. (Investor Relations)
Matthew Hayden or Brett Maas, 843-272-4653
matt@haydenir.com
CVQ-T NR today 102m at 3.47
CV begins trading on TSX; to enter U.S. market
2006-03-22 08:08 ET - News Release
Mr. Gordon Brown reports
CV TECHNOLOGIES-MAKER OF COLD-FX'R'-BEGINS TRADING ON THE TSX
CV Technologies Inc. today began trading its common shares on the Toronto Stock Exchange, trading under the symbol (CVQ), previously used on the TSX Venture Exchange.
CV Technologies was selected the TSX Venture Exchange's top performing company in 2005. CV Technologies president and chief executive officer Dr. Jacqueline Shan says: "This move fulfills a major corporate objective that management had set for this year. We believe our investors will see this as a natural and timely progression in our development. It is part of our business plan and coincides with our announcement at our annual general meeting three weeks ago of our strategy to enter the U.S."
Dr. Shan added, "A listing on the TSX could bring our company more visibility, attract analysts and institutional investors, and offer more stability to the company in the capital markets."
As part of the listing ceremony, Dr. Shan, along with COLD-fX spokesperson Don Cherry and other company executives, launched the trading day on the TSX.
A good move I believe.
OTG
DJE-V NR today
Dejour to begin Athabasca drill program April 1
2006-03-21 14:08 ET - News Release
Mr. Robert Hodgkinson report
DRILLING TO COMMENCE ON DEJOUR'S ATHABASCA URANIUM PROJECTS
Dejour Enterprises Ltd. providing progress reviews on a drilling program and its other 100-per-cent-owned uranium exploration projects in the Athabasca basin, Northern Saskatchewan in Canada.
The company reports that the winter exploration program in the basin is on schedule. The company is the operator. Hy-Tech Drilling of Smithers, B.C., has mobilized its drill to the site. Hy-Tech is contracted to carry out 5,000 metres of drilling scheduled to begin by April 1, 2006. The drill holes will test targets defined by Dejour's airborne and ground geophysical work carried out in 2005 and 2006, and will test anomalous radioactivity and sandstone alteration intersected in drilling by previous operators.
Fuel for the helicopter-supported drilling program has been hauled to the Dejour camp site. Sufficient aviation fuel and diesel have also been brought in and stored on-site to carry out additional drilling and ground geophysics during Dejour's summer exploration program.
Geophysical surveying is currently being conducted by crews from Patterson Geophysics Inc. of La Ronge, Sask., which has worked in the Athabasca basin for over 20 years. The Patterson crews are testing selected portions of the 250-line kilometres of EM conductors detected by Dejour's 2005 airborne surveys. This groundwork is scheduled for completion by month-end. Field data are available on a daily basis, and are checked and interpreted by Dejour's geophysical consultant in Vancouver. The results from these geophysical surveys will guide the winter drill program.
Dejour is also planning an aggressive summer exploration program consisting of:
ground geophysics to follow up airborne EM anomalies;
3,000 plus kilometres of airborne EM surveying to test properties not surveyed in 2005 and to test and extend the anomalies on ground that Dejour staked in 2005, as a result of the 2005 deep-penetrating Megatem surveys;
Boulder lithogeochemical surveys to follow up on anomalous results from the 2005 sampling program;
state-of-the-art deep-penetrating ground geophysics to test the prospective, but deep, Virgin Trend North property; and
additional diamond drilling.
As previously noted, Dejour has hauled to and stored on-site sufficient avgas and diesel to carry out this exploration program.
J. Allan McNutt, PGeo, MA, Sc, is the qualified person for Dejour's uranium projects.
URE-T NR today
Ur-Energy expands U3O8 base to 84.64 million pounds
2006-03-21 10:24 ET - News Release
Mr. Bill Boberg reports
UR-ENERGY INC. UPDATES HISTORICAL RESOURCE BASE TO EXCEED 80 MILLION POUNDS U3O8
The extensive database which is owned by Ur-Energy Inc. demonstrates that Ur-Energy's properties in Wyoming contain historical resources exceeding 80 million pounds U3O8 (uranium). These resources are not National Instrument (NI) 43-101-compliant, but are quoted as previously calculated resource estimates by major mining companies or qualified consultants that worked on the properties prior to Ur-Energy's involvement.
Previously, Ur-Energy carried its relevant historic resources at 19 million pounds, at a time when the company had made purchase agreements with the landholders. Since then Ur-Energy has hired an exceptional staff of uranium geologists and mining engineers, and has had the opportunity to examine tens of thousands of files, drill logs, plans and drill sections and reports.
In addition, the company purchased a significant database from a major company on certain of its properties in Wyoming. "The combination of both databases provided an incredible amount of additional information which significantly changed our historical resource inventory," said Bill Boberg, president and chief executive officer of Ur-Energy. "Our people have been working diligently for the past year to absorb a tremendous amount of data, none of which was digital, therefore delaying our release of an update on the company's properties. "We are pleased to now be able to provide historical resources on the claims we hold in Wyoming. However, our historical resource inventory is not yet complete; additional updates will be released as we continue our literature and data compilation."
Ur-Energy controls nine properties in Wyoming, one of the most mining-friendly states in the United States to explore for and mine uranium. The current Governor of Wyoming has endorsed the fact that the state is open for business in all areas of resource development, including uranium.
Of the nine properties held by Ur-Energy, five are in the Great Divide basin; two of these (Lost Soldier and Lost Creek) contain major, well drill-defined historical resources. The company previously reported (Ur-Energy news release in Stockwatch dated Jan. 23, 2006) that it had completed a drilling program which will lead to a NI 43-101-defined resource and will enable Ur-Energy to rapidly advance both deposits to production. At Lost Soldier, production is expected to start as early as 2008.
The table below presents the gross historical resources defined in the company database by property:
Project/ Report Historical
historic date resource
operator lb. U3O8
(avg. % U3O8)
Lost Soldier
project
Cameco Corp.
AIF 1998 26,620,000
(n/a)
Lost Creek
project
Conoco --
Texasgulf 1978 12,800,000
(0.044%)
Radon Springs
project
Texasgulf 1978 34,319,000
(0.020%)
North Hadsell
Richard
Fruchey 1991 7,700,000
(n/a)
Kaycee
Washtenaw
Energy Corp. 1982 and 3,204,000
& Fruchey 1978 (0.11%)
& Eichorn
----------
Total 84,643,000
==========
Note: (The resources stated above are historical in nature and were compiled before the implementation of NI 43-101 reporting standards. Recent independent verification of the data have not been performed, except for the Lost Soldier and Lost Creek deposits whereby the company is currently determining an NI 43-101-compliant resource estimate. The company has not completed sufficient exploration on its other properties to verify the historical resource estimates. The historical resources were prepared to industry standards in place at the time and are considered relevant today. The historical resources noted above are not in agreement with the CIM definitions as required by NI 43-101-defined resources or reserves verified by a qualified person and the historical estimates should not be relied upon.)
The qualified person in the United States for Ur-Energy Inc., as defined by NI 43-101, is W. William Boberg, president and chief executive officer.
We seek Safe Harbor.
NVAX NR 21/03/06 NR 8.31
Novavax Executes Definitive Agreement for $38 Million Public Offering
2006-03-21 07:50 ET - News Release
MALVERN, Pa., March 21 /PRNewswire-FirstCall/ -- Novavax, Inc. today announced that it has entered into a definitive agreement for a $38 million registered direct offering of 5,205,479 shares of its common stock at a price of $7.30 per share. The shares of common stock will be issued pursuant to an effective shelf registration statement.
Rodman & Renshaw, LLC acted as the exclusive placement agent for the offering. Novavax plans to use the net proceeds from the offering for general corporate purposes, including but not limited to i) clinical development of virus-like particles (VLP) based avian and seasonal influenza vaccines, including the development of appropriate adjuvants, and demonstration of large-scale production capabilities, for such vaccines; ii) internal research and development programs, such as preclinical and clinical testing and studies of our product candidates and the development of new technologies; iii) expansion of and investment in the Company's research and development facilities, including compliance with CGMP (Current General Manufacturing Practices) and GLP (Good Laboratory Practices) rules and regulations and iv) other general corporate purposes. A copy of the final prospectus relating to the offering may be obtained from Dennis Genge, Vice President and Chief Financial Officer, Novavax, Inc., 508 Lapp Road, Malvern, PA 19355, when available.
About Novavax, Inc.
Novavax is focused on creating differentiated, value-added pharmaceutical and vaccine products and technologies. The company's technology platforms include the virus-like particle (VLP) manufacturing technology utilizing the baculovirus expression system in insect cells, as well as novel vaccine adjuvants based on Novasome(R) non-phospholipid vesicles and dendrimer technologies. The company is developing a pandemic flu vaccine against H5N1, H9N2 and other avian influenza viruses and a seasonal flu vaccine against human influenza strains using its VLP and Novasome adjuvant technologies. Novavax's drug delivery technologies include the micellar nanoparticle (MNP) technology which is the basis for the development of its first FDA-approved product, ESTRASORB(R). In addition to MNP, Novavax drug delivery technologies include Novasomes and Sterisome(R) solvent and oil free emulsions for subcutaneous depot injection. The company has several products utilizing the MNP technology in various stages of development.
Forward Looking Statements
Statements made in this press release that state Novavax's or management's intentions, hopes, beliefs, expectations, or predictions of the future are forward-looking statements. Forward-looking statements include but are not limited to statements regarding usage of cash, product sales, future product development and related clinical trials and future research and development, including FDA approval. Novavax's actual results could differ materially from those expressed in such forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among other things, the following: general economic and business conditions; ability to enter into future collaborations with industry partners, competition; unexpected changes in technologies and technological advances; ability to obtain rights to technology; ability to obtain and enforce patents; ability to commercialize and manufacture products; ability to establish and maintain commercial-scale manufacturing capabilities; results of clinical studies; progress of research and development activities; business abilities and judgment of personnel; availability of qualified personnel; changes in, or failure to comply with, governmental regulations; the ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity financing or otherwise; and other factors referenced herein. Additional information is contained in Novavax's annual report on Form 10K for the year ended December 31, 2005 incorporated herein by reference. Statements made herein should be read in conjunction with Novavax's annual and quarterly reports filed with the SEC. Copies of these filings may be obtained by contacting Novavax at 508 Lapp Road, Malvern, PA 19355 Tel 484-913-1200 or the SEC at http://www.sec.gov.
Novavax, Inc.
CONTACT: Kathy Hamilton of Novavax, Inc., +1-484-913-1213,
KHamilton@novavax.com
Web site: http://www.novavax.com/
NVAX NR 20/03/06
Novavax CEO to Present at World Vaccine Congress 2006
2006-03-20 07:00 ET - News Release
MALVERN, Pa., March 20 /PRNewswire-FirstCall/ -- Novavax, Inc. , today announced that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax, is scheduled to make a presentation at the World Vaccine Congress 2006 in Washington, DC on Tuesday, March 21, 2006. The conference will be held at the Four Seasons Hotel in Washington, DC and Dr. Singhvi will present at 5:50 p.m. ET. Dr. Singhvi's presentation will include a case study on Novavax's potential pandemic virus-like particle (VLP) flu vaccine initiative, a new vaccine platform to address the urgent need for a pandemic flu vaccine which includes:
* Results of pre-clinical studies with an influenza avian (pandemic) H9N2
candidate VLP vaccine
* Novasomes(R) -- a safe, patented adjuvant to help address the need for
antigen sparing
* Rapid, disposable, scalable manufacturing process to meet vaccine needs
for pandemic flu
About Novavax, Inc.
Novavax is focused on creating differentiated, value-added pharmaceutical and vaccine products and technologies. The company's technology platforms include the virus-like particle (VLP) manufacturing technology utilizing the baculovirus expression system in insect cells, as well as novel vaccine adjuvants based on Novasomes(R), non-phospholipid vesicles and dendrimer technologies. The company is developing a pandemic flu vaccine against H5N1, H9N2 and other avian influenza viruses and a seasonal flu vaccine against human influenza strains using its VLP and Novasome adjuvant technologies. Novavax's drug delivery technologies include the micellar nanoparticle (MNP) technology which is the basis for the development of its first FDA-approved product, ESTRASORB(R). In addition to MNP, Novavax drug delivery technologies include Novasomes(R) and Sterisomes(R), solvent and oil free emulsions for subcutaneous depot injection. The company has several products utilizing the MNP technology in various stages of development.
Forward Looking Statements
Statements made in this press release that state Novavax's or management's intentions, hopes, beliefs, expectations, or predictions of the future are forward-looking statements. Forward-looking statements include but are not limited to statements regarding usage of cash, product sales, future product development and related clinical trials and future research and development, including FDA approval. Novavax's actual results could differ materially from those expressed in such forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among other things, the following: general economic and business conditions; ability to enter into future collaborations with industry partners, competition; unexpected changes in technologies and technological advances; ability to obtain rights to technology; ability to obtain and enforce patents; ability to commercialize and manufacture products; ability to establish and maintain commercial-scale manufacturing capabilities; results of clinical studies; progress of research and development activities; business abilities and judgment of personnel; availability of qualified personnel; changes in, or failure to comply with, governmental regulations; the ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity financing or otherwise; and other factors referenced herein. Additional information is contained in Novavax's annual report on Form 10K for the year ended December 31, 2005 incorporated herein by reference. Statements made herein should be read in conjunction with Novavax's annual and quarterly reports filed with the SEC. Copies of these filings may be obtained by contacting Novavax at 508 Lapp Road, Malvern, PA 19355 Tel 484-913-1200 or the SEC at www.sec.gov.
Novavax, Inc.
CONTACT: Kathy Hamilton of Novavax Inc., Investor Relations,
+1-484-913-1213, khamilton@novavax.com
Web site: http://www.novavax.com//
CVQ-V NR 06/20/06 102m at 3.30
CV Technologies to list on TSX on March 22
2006-03-20 19:02 ET - New Listing
TSX bulletin 2006-0307
An application has been granted for the original listing in the industrial category of 117,418,950 Class A common shares of which 102,013,340 Class A common shares are issued and outstanding, and 15,405,610 Class A common shares are reserved for issuance. The Class A common shares of the company will be listed and posted for trading at the open on Wednesday, March 22, 2006.
Stock symbol: CVQ
Cusip No.: 126664 10 1
Trading currency: Canadian dollars
Designated market-maker: RBC Capital Markets
Other markets: The Class A common shares of the company were listed on the TSX Venture Exchange on July 27, 1998. The Class A common shares will be delisted from the TSX-V on March 22, 2006.
Incorporation: The issuer was incorporated under the Business Corporation Act of Alberta on June 29, 1992. Effective Oct. 1, 1997, the issuer amalgamated with Corsayre Capital Co. on the Alberta Stock Exchange. Effective June 30, 1998, the issuer and HerbTech Inc., a former wholly owned subsidiary of the issuer, amalgamated and continued as CV Technologies Inc.
Fiscal year-end: Sept. 30
Nature of business: The issuer is a health sciences and technology company, founded in 1992 and headquartered in Edmonton, Alta. The issuer has developed, commercialized and patented a proprietary technology used to discover and biologically standardize natural products that deliver consistent, verifiable and provable health benefits. The issuer's lead product, COLD-fX, is designed to prevent and treat colds and flu by strengthening the immune system.
Transfer agent and registrar: Computershare Trust Co. of Canada at its principal offices in Toronto and Calgary
Dividends: The company will consider paying dividends if/as and when the financial position would allow the payment of dividends.
I know a number of traders who use Interactive Brokers, among others. I would google it and check each out. It depends on limits, trade needs etc.
CVQ-V NR today 102m at 3.00
CV Technologies to list on TSX March 22
2006-03-20 09:49 ET - News Release
Dr. Jacqueline Shan reports
CV Technologies Inc. has received approval to begin trading of its common shares on the Toronto Stock Exchange beginning Wednesday, March 22, 2006. The company will continue to trade under the symbol CVQ. CVQ will be delisted from the TSX Venture Exchange at the close of trading Tuesday, March 21, 2006.
CV Technologies was selected the TSX Venture Exchange's top performing company in 2005. CV Technologies president and chief executive officer Dr. Jacqueline Shan says: "This move fulfills a major corporate objective that management had set for this year. We believe our investors will see this as a natural and timely progression in our development. It is part of our business plan and coincides with our announcement of our strategy to enter the U.S. at our annual general meeting three weeks ago.
"A listing on the TSX could bring our company more visibility, attract analysts and institutional investors and offer more stability to the company in the capital markets."
As part of the listing ceremony this Wednesday, Dr. Shan, along with other company executives, will launch the trading day on the TSX at 9:30 a.m. Wednesday.
We seek Safe Harbor.
Yes, I have heard of the problems that have been encountered. This is the same issue that came up when O&G drilling first started.
The seismic activity near the surface causes shifts in the subsurface water flow (Read dry wells).
I can't see the major players not agree to drill new water wells for those affected if necessary to solve their water problems. A deeper water well often solves the problem (In some locations, at least).
No doubt there will be adjustments on both sides before regulation is settled in this dispute.
Thanks for the link - They are looking good now.
May just have to grab a few this next week.
DJE-V daily 3 month chart
URE-T daily 3 month chart
MPH-T daily chart 3 month
RBM-V daily 3 month chart
GNBT daily 3 month chart
NVAX daily chart 3 month
JW have you been watching this one? A Casey pick RIX.v
Bruce check out this site: http://www.investopedia.com/
They have lots of good information for a newbie. Watch the indexes for the types of stocks you are looking to purchase. Check out the charts.
Buy low & sell Hi - Should be your goal. Remember to chart the stocks in the time frame you are looking at holding them Weekly for Long Term holds, Daily for medium or Swing trades and Intra day (1-5-15-30-60 min) charts for Day trades. Using the Moving averages as buy and sell points.
Good luck with your trading.
OTG
PTI-T 6.71 - Sedar today
Remember GNBT seems to be about a day behind NVAX.
Good luck with your trades.
NVAX - Correction
/C O R R E C T I O N -- Novavax, Inc./
2006-03-16 09:04 ET - News Release
In the news release, Novavax Receives Additional Government Funding for IV/AIDS Vaccine Research, issued earlier today by Novavax, Inc. over PR Newswire, the headline should read "Novavax Receives Additional Government Funding for HIV/AIDS Vaccine Research" rather than "IV/AIDS Vaccine Research" as incorrectly transmitted by PR Newswire.
Novavax, Inc.
DDS-T NR today 43m at 7.75
Globe says former Labopharm chair settles with OSC
2006-03-17 07:05 ET - In the News
The Globe and Mail reports in its Friday edition that Ian Lennox has reached a settlement with the Ontario Securities Commission on accusations of illegal insider trading. The Globe's Janet McFarland writes in the Business Ticker column that Mr. Lennox is the former chairman of pharmaceutical company Labopharm. The OSC announced Thursday that Mr. Lennox has agreed to pay $32,000 plus $5,000 in costs. Mr. Lennox has also agreed to take a governance course at the University of Toronto's Rotman School of Management. Mr. Lennox was accused of buying 25,000 shares of Labopharm last August while in possession of undisclosed information about a new partnership agreement. Labopharm stock closed off four cents at $7.75 Thursday in Toronto. The stock has a 52-week trading range of $9.75 to $2.50. The stock began a significant advance in early November, peaking at the end of January. The United States Food and Drug Administration agreed to review Labopharm's filing to sell a once-daily version of the pain reliever tramadol in late January. The Globe reported on Jan. 31 that National Bank Financial analyst Andre Uddin said the the likelihood of FDA "approval is very good." The stock has since fallen $2.45.
GNBT NR today 2.45
Generex Biotechnology Receives Patent in Mexico
2006-03-16 09:00 ET - News Release
TORONTO -- (MARKET WIRE) -- 03/16/06
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=113474&ProfileId=051205&am...
Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, announced today that it has been granted a patent by the Mexico National Registry of Patents titled "Proteinic Drug Delivery System Using Aerosolized Membrane-Mimetic Amphiphiles." The patent, an extant United States Patent registered by the Company, relates to an improved delivery system for the administration of large-molecule pharmaceuticals, particularly through the oral and nasal membranes.
The patent covers formulations for the delivery of peptidic drugs, vaccines, and hormones and enhances the Company's existing drug delivery platform patent portfolio.
"We are pleased to augment our Latin American patent protection as we continue with our Generex Oral-lyn(TM) commercialization efforts in the region," said Rose Perri, the Company's Chief Operating Officer. Generex Oral-lyn is the Company's flagship product, a proprietary oral insulin spray product which has been approved by the Ecuadorian Ministry of Public Health for the treatment of Type-1 and Type-2 diabetes.
The Company currently holds an aggregate of 71 patents (19 of which are United States patents) and has an aggregate 58 patent applications pending in various jurisdictions.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.
For more information, visit the Generex Web site at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Contact:
Shayne Gilliatt
Generex Biotechnology Corporation
Phone: (800) 391-6755
and (416) 364-2551
Ed Lewis
CEOcast, Inc.
Phone: 1 (212) 732-4300
CJC-T NR today 47M at 1.24
ConjuChem loses $9.73-million in Q1
2006-03-16 09:13 ET - News Release
Mr. Lennie Ryer reports
CONJUCHEM ANNOUNCES FISCAL 2006 FIRST QUARTER FINANCIAL RESULTS
ConjuChem Inc. has provided its financial results for its first quarter of fiscal 2006, ended Jan. 31, 2006.
"ConjuChem is making solid progress on the clinical front as 2006 advances. Subsequent to quarters end, we received clearance from the FDA to conduct a phase I/II trial for the treatment of Type 2 diabetes using our proprietary PC-DAC: Exendin-4 compound. At the same time, our phase II study for DAC:GRF for the treatment of HIV-related Lipodystrophy remains ongoing," said vice-president and chief financial officer Lennie Ryer. "We look forward to updating shareholders on these two lead programs as the year progresses."
The company's net loss for the quarter ended Jan. 31, 2006, was $9.7-million, or 20 cents per share, compared with $11.3-million, or 26 cents per share, for the quarter ended Jan. 31, 2005. The decrease in the net loss is mainly attributable to a decrease in net research and development expenses of $1.7-million.
The company recorded interest income on cash, short and long-term investments of $80,886 for the quarter versus $137,775 in the same period last year. The decrease in interest revenue was a result of lower rates of return on invested funds caused by a general decrease in market interest rates combined with a reduction in the funds available for investment.
Net research and development expenses amounted to $6.1-million for the quarter ended Jan. 31, 2006, compared with $7.9-million in the same period last year. The decrease is largely attributable to reduced costs of the clinical development programs compared with the prior fiscal year.
General and administrative costs for the quarter ended Jan. 31, 2006, were $1.2-million compared with $929,442 for the same period last year. The increase in general and administrative expenses is attributable to increased costs of insurance coverage and non-recurring expenses incurred to recruit and relocate ConjuChem's new president and chief executive officer.
As of Jan. 31, 2006, the company had cash and cash equivalents of $9.9-million and a working capital position of $7.5-million.
Subsequent to quarter-end, ConjuChem announced a corporate reorganization transaction which will strengthen its financial position by adding an extra $6.4-million of gross proceeds to ConjuChem's balance sheet. The transaction, which will monetize accumulated tax losses, in no way changes the fundamental business of the company and is non-dilutive for its shareholders.
Outlook
ConjuChem anticipates releasing preliminary data from its phase I/II trial for the treatment of Type 2 diabetes using its proprietary PC-DAC:Exendin-4 compound by midyear. A maximum of 68 patients will be enrolled in this randomized, double-blind, single escalating dose study with patient dosing to begin by mid-March. The company's placebo-controlled, double-blind phase II study in which DAC:GRF is administered once weekly for the treatment of HIV-related Lipodystrophy remains continuing. ConjuChem expects to report preliminary data from this trial in the fourth quarter of 2006.
STATEMENT OF OPERATIONS AND DEFICIT
Three months ended Jan. 31
2006 2005
Revenues
Contract
revenue $239,123 $32,989
Interest
income 80,886 137,775
------------ ------------
320,009 170,764
Expenses
Research
and
development 6,214,332 8,027,938
Investment
tax credits (75,000) (150,000)
------------ ------------
Net
research
and
development
expenses 6,139,332 7,877,938
General and
admin
expenses 1,203,960 929,442
Amortiz-
ation of
property,
plant and
equipment 72,814 93,704
Amortiz-
ation of
intangible
assets 14,486 10,391
Amortiz-
ation of
deferred
financing
fees 8,722 8,722
Non-cash
stock
compens-
ation 1,183,343 1,280,198
Financial
charges 3,673 3,501
Foreign
exchange
(gain) loss 184 96,179
Accretion
in carrying
value of
convertible
senior
unsecured
notes 1,425,799 1,204,650
------------ ------------
10,052,313 11,504,725
------------ ------------
Net (loss) $(9,732,304) $(11,333,961)
============ ============
(Deficit),
beginning
of period $(200,918,066) $(157,056,878)
Opening
adjustment
for stock-
based
compen-
sation - (5,343,453)
------------ ------------
(Deficit),
end of
period $(210,650,370) $(173,734,292)
============ ============
Basic and
diluted
(loss) per
share $(0.20) $(0.26)
We seek Safe Harbor.
HEB NR 3.22
New Research From Hemispherx Biopharma Leverages Recent Studies to Identify Factors in Breakdown of Immune System; May Help Prevent Spread of Avian Flu
2006-03-16 08:25 ET - News Release
PHILADELPHIA -- (Business Wire) -- March 16, 2006
Company Website: http://www.hemispherx.net
Hemispherx Biopharma, Inc.:
-- Results to be Presented at the VIII International Symposium on
Respiratory Viral Infections March 16-19 in Hawaii
-- Japanese Researchers Initiate Primate Studies With
Co-administration of Hemispherx Biopharma's Ampligen and H5N1
Vaccine
The results of new studies to be presented at the VIII
International Symposium on Respiratory Viral Infections on March 16-19
represent a major step forward in leveraging research that identifies
the gene that is believed to have caused the immune system to shut
down and led to the devastating Spanish flu epidemic of 1918, which is
estimated to have killed 100 million people. These studies have
critical implications because some researchers believe the current
spread of the H5N1, or avian flu, virus may have similar underlying
causes. The findings, to be presented by Dr. William Mitchell,
Professor of Pathology at Vanderbilt University and a member of the
Board of Directors of Hemispherx Biopharma, provide further evidence
that Hemispherx Biopharma's Alferon LDO (Low-Dose Oral), a new
delivery form of an anti-viral with prior regulatory approval for a
category of sexually transmitted diseases, has tremendous potential in
resisting the spread of avian flu by stimulating genes that induce the
production of immune compounds that are key building blocks in the
body's defense system.
Researchers in this area have recently focused on TNF, a naturally
occurring immune substance (or "lymphokine") as the instigator of the
massive tissue damage to lung cells. The new research included
analysis of avian flu virus specimens recently recovered in the frozen
arctic tundra from victims of the 1918 avian flu epidemic. These
studies suggest that the interferon system, the body's primary line of
defense, broke down first, leading to the aberrant and ultimately
self-destructive release of TNF.
In recent healthy human volunteer tests conducted in Hong Kong and
Philadelphia, patients were given graded doses of Alferon LDO for two
minutes' exposure. Blood samples were then taken to determine which
components of the immune system had been activated. It was found that
the interferon gene activity normally suppressed or killed by the
virus were instead enhanced several times over. By contrast, the TNF
gene battery normally enhanced by viral infection was instead sharply
suppressed by the brief Alferon LDO exposure.
"These new studies are highly significant to our understanding of
how the body reacts to virus attacks, a critical component in building
adequate defenses against the spread of avian flu," said Dr. William
Mitchell. "We believe that taken collectively, the latest findings
represent tremendous progress in this critical area."
Dr. Mitchell will also be presenting ongoing findings from trials
on The TLR3 Agonist, Poly I: Poly C12U, Provides Nasal Adjuvant
Activity to a Vaccine Directed Against Highly Pathogenic H5N1 Avian
Influenza Virus and Synerginistic Inhibition of Avian Influenza Virus
(H5N1) by PolyI: Poly C12 U Combined with Oseltamivir or Zanamivir.
(All three trials were recently presented at the ASM Biodefense
Conference.)
Dr. Mitchell will announce that the co-administration of
Hemispherx Biopharma's experimental immunotherapeutic Ampligen, a
specifically configured double-stranded RNA, may help enable
substantial reductions in an H5N1 vaccine dose, as well as provide
cross-protection against mutated strains of the H5N1 virus. These
results come from a conclusive mouse study conducted in collaboration
with the National Institute of Infectious Diseases in Japan. In
collaboration with Hemispherx Biopharma, the Institute has initiated
the next phase of studies with primates.
Finally, additional research to be presented suggests the
effectiveness of Tamiflu and Relenza, the only two drugs formally
recognized for combating bird flu, can be boosted up to 100 times. Lab
studies reveal that 50 to 100 times less Tamiflu may be used in
conjunction with Ampligen to achieve full inhibition with no
multiplication of the virus, and no host cell damage.
"The latest research offers further evidence that we are on the
right path to identifying the factors that cause the immune system to
break down, which has grave implications in the event of a pandemic,"
said Dr. William A. Carter, M.D., Chairman and CEO of Hemispherx
Biopharma. "We're also encouraged that our experimental
immunotherapeutics Ampligen and Alferon offer tremendous potential
against the global spread of the H5N1 virus."
About Hemispherx Biopharma
Hemispherx Biopharma, based in Philadelphia, is a
biopharmaceutical company engaged in the manufacture and clinical
development of new drug entities for treatment of viral and
immune-based chronic disorders. Hemispherx Biopharma's flagship
products include Alferon(R) and the experimental
immunotherapeutics/antivirals Ampligen(R) and Oragens(TM). Alferon(R)
is approved for a category of STD infection, and Ampligen(R) and
Oragens(TM) represent experimental nucleic acids being developed for
globally important viral diseases and disorders of the immune system.
Hemispherx's platform technology includes large and small agent
components for potential treatment of various chronic viral
infections. Hemispherx has in excess of 140 patents comprising its
core intellectual property estate, a fully commercialized product
(Alferon(R) N) and GMP certified manufacturing facilities for its
novel pharma products. For more information please visit
www.hemispherx.net
www.hemispherx.net
Information contained in this news release other than historical
information, should be considered forward-looking and is subject to
various risk factors and uncertainties. For instance, the strategies
and operations of Hemispherx involve risk of competition, changing
market conditions, change in laws and regulations affecting these
industries and numerous other factors discussed in this release and in
the Company's filings with the Securities and Exchange Commission. Any
specifically referenced investigational drugs and associated
technologies of the company (including Ampligen(R), Alferon(R) LDO and
Oragens) are experimental in nature and as such are not designated
safe and effective by a regulatory authority for general use and are
legally available only through clinical trials with the referenced
disorders. The forward-looking statements represent the Company's
judgment as of the date of this release. The Company disclaims,
however, any intent or obligation to update these forward-looking
statements. Clinical trials for other potential indications of the
approved biologic Alferon(R) do not imply that the product will ever
be specifically approved commercially for these other treatment
indications.
Contacts:
Hemispherx Biopharma, Inc.
Dianne Will, 518-398-6222
ir@hemispherx.net
or
Media:
Neale-May & Partners
Digs Majumder, 212-213-5400 x206
digs@nealemay.com
NVAX NR 7.00
Novavax Receives Additional Government Funding for IV/AIDS Vaccine Research
2006-03-16 07:00 ET - News Release
MALVERN, Pa., March 16 /PRNewswire-FirstCall/ -- Novavax, Inc. , announced approval today from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), of an additional commitment of approximately $1.0 million to fund the third year of a 4 1/2 year research program. Novavax is developing a novel HIV/AIDS virus-like particle (VLP) vaccine as part of an NIH Integrated Preclinical/Clinical AIDS Vaccine Development Program comprised of scientists from the University of Alabama at Birmingham, Emory University, and Harvard Medical School. All three institutions are working with Novavax in a collaboration to accelerate HIV/AIDS vaccine development.
Dr. Gale Smith, Vice President of Vaccine Development, explains, "We believe the only realistic solution to the global HIV/AIDS pandemic is an effective vaccine. Novavax is extremely pleased to be working with such an acknowledged group of world leaders in developing a novel HIV/AIDS vaccine. Our research is based on our insect cell technology for the production of recombinant virus particles that mimic HIV-1, but without the risk of infection." According to Dr. Beatrice Hahn, one of the principal investigators at the University of Alabama at Birmingham, "Globally circulating strains of HIV-1 are extraordinarily variable, and this diversity poses a major obstacle to AIDS vaccine development. Currently, all candidate vaccines are derived from contemporary HIV-1 isolates, often selected solely based on availability. With VLP vaccines produced by Novavax, we are now testing whether consensus immunogens can elicit broadly cross-reactive immune responses and thus protect against a wide range HIV-1."
In the first two years of the program, Novavax developed a process to manufacture HIV-1 VLPs from consensus sequences of the HIV-1 envelope glycoprotein, the principle target for virus neutralization. These synthetic genes were shown to be incorporated into particles that are structurally similar to HIV-1. Scientists at UAB, Emory, and Harvard discovered that the novel HIV/AIDS VLP vaccines induced a range of immune responses and antibodies in small animals and non-human primates that neutralized both laboratory strains and acute, contemporary HIV-1 isolates. The objectives for the team during 2006 are to maximize efficiency of incorporation of the HIV-1 envelope glycoprotein into particles. Novavax then plans to begin preparations for human clinical trials of an improved HIV/AIDS VLP vaccine.
About HIV/AIDS Pandemic
According to a 2005 report from the World Health Organization (WHO), HIV/AIDS has killed more 25 million people, making it one of the most destructive epidemics in recorded history. HIV claimed the lives of more than half a million children and about 3.1 million people overall in 2005. In the United States alone, more than 40,000 become infected with HIV annually.
About Virus-Like Particle (VLP) Technology
Novavax's virus-like particle (VLP) vaccines use recombinant DNA technology to produce antigenic structures that mimic a virus to produce a protective immune response without the risk of infection or disease. Viral proteins can self-assemble into VLPs when over-expressed in certain cells. The use of VLP technology has already been proven with the success of the hepatitis B vaccine and more recently with developmental human papillomavirus vaccines. This is the first time that VLP technology has been applied to create a potential HIV/AIDS vaccine and is the same technology Novavax is using to produce influenza VLP vaccines that are readily adaptable and could be scaled up to meet a surge in demand during a pandemic.
About Novavax, Inc.
Novavax is focused on creating differentiated, value-added pharmaceutical and vaccine products and technologies. The company's technology platforms include the virus-like particle (VLP) manufacturing technology utilizing the baculovirus expression system in insect cells, as well as novel vaccine adjuvants based on Novasomes(R), non-phospholipid vesicles and dendrimer technologies. The company is developing a pandemic flu vaccine against the H5N1, H9N2 and other avian influenza viruses and a season flu vaccine against human influenza strains using its VLP and Novasome adjuvant technologies. Novavax's drug delivery technologies include the micellar nanoparticle (MNP) technology which is the basis for the development of its first FDA-approved product, ESTRASORB(R). In addition to MNP, Novavax drug delivery technologies include Novasomes(R) and Sterisomes(R), solvent and oil free emulsions for subcutaneous depot injection. The company has several products utilizing the MNP technology in various stages of development.
Forward Looking Statements
Statements made in this press release that state Novavax's or management's intentions, hopes, beliefs, expectations, or predictions of the future are forward-looking statements. Forward-looking statements include but are not limited to statements regarding usage of cash, product sales, future product development and related clinical trials and future research and development, including FDA approval. Novavax's actual results could differ materially from those expressed in such forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among other things, the following: general economic and business conditions; ability to enter into future collaborations with industry partners, competition; unexpected changes in technologies and technological advances; ability to obtain rights to technology; ability to obtain and enforce patents; ability to commercialize and manufacture products; ability to establish and maintain commercial-scale manufacturing capabilities; results of clinical studies; progress of research and development activities; business abilities and judgment of personnel; availability of qualified personnel; changes in, or failure to comply with, governmental regulations; the ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity financing or otherwise; and other factors referenced herein. Additional information is contained in Novavax's annual report on Form 10K for the year ended December 31, 2005 incorporated herein by reference. Statements made herein should be read in conjunction with Novavax's annual and quarterly reports filed with the SEC. Copies of these filings may be obtained by contacting Novavax at 508 Lapp Road, Malvern, PA 19355 Tel 484-913-1200 or the SEC at www.sec.gov.
Novavax, Inc.
CONTACT: Kathy Hamilton, Investor Relations of Novavax Inc.,
+1-484-913-1213, khamilton@novavax.com
ONC-T NR today 36m at 5.85
Oncolytics to present Reolysin data at conference
2006-03-16 06:45 ET - News Release
An anonymous director reports
ONCOLYTICS BIOTECH INC.'S RESEARCH COLLABORATORS TO PRESENT REOLYSIN(R) CLINICAL TRIAL DATA AT ASCO CONFERENCE
Research collaborators with Oncolytics Biotech Inc. are scheduled to deliver two poster presentations covering Reolysin clinical trial data at the American Society of Clinical Oncology (ASCO) annual meeting, to be held June 2 to 6, 2006, in Atlanta, Ga. The data cover interim results of Oncolytics's phase I systemic administration trial being conducted in the United Kingdom, and final results of Oncolytics's Canadian phase I recurrent malignant glioma trial.
A poster entitled, "A phase I study of a wild-type reovirus (Reolysin) given intravenously to patients with advanced malignancies," is scheduled to be presented by Dr. Johann S. de Bono of the Royal Marsden Hospital and the Institute of Cancer Research, U.K.
A poster entitled, "A phase I trial of intratumoral (i.t.) administration of reovirus in patients with histologically confirmed recurrent malignant gliomas (MGs)," is scheduled to be presented by Dr. P.A. Forsyth of the University of Calgary and the Alberta Cancer Board.
We seek Safe Harbor.
CJC-T Sedar report today
APT NR today
Alpha Pro Tech, Ltd. to Announce 2005 Fourth Quarter and Year End Results on March 22, 2006
2006-03-15 11:32 ET - News Release
NOGALES, Ariz -- (Business Wire) -- March 15, 2006
Alpha Pro Tech (AMEX:APT)(CHX:APT), a leading
manufacturer of products designed to protect people and environments,
including disposable protective apparel and construction supply
weatherization products, announced today that it will have a
conference call regarding its 2005 fourth quarter and year end
financial results, which ended on December 31, 2005.
The conference call will take place at 4:30 p.m. Eastern Time, on
Wednesday, March 22, 2006. Anyone interested in participating should
call 800-811-0667 if calling within the United States or 913-981-4901
if calling internationally. There will be a playback available until
April 5, 2006. To listen to the playback, please call 888-203-1112 if
calling within the United States or 719-457-0820 if calling
internationally. Please use pin number 4323280 for the replay.
This call is being web cast by ViaVid Broadcasting and can be
accessed at Alpha Pro Tech's website at www.alphaprotech.com. The web
cast may also be accessed at ViaVid's website at www.viavid.net. The
web cast can be accessed until April 22, 2006 on either site.
To access the web cast, you will need to have the Windows Media
Player on your desktop. For the free download of the Media Player
please visit:
http://www.microsoft.com/windows/windowsmedia/en/download/default.asp.
About Alpha Pro Tech, Ltd.
Alpha Pro Tech, Ltd. develops, manufactures and markets innovative
disposable and limited-use protective apparel products for the
industrial, clean room, medical and dental markets. In addition, Alpha
ProTech Engineered Products, Inc. manufactures and markets a line of
construction weatherization products, including building wrap, roof
underlayment and mold resistant framing sealant. The Company has
manufacturing facilities in Salt Lake City, Utah; Nogales, Arizona;
Janesville, Wisconsin; and Valdosta, Georgia. For more information and
copies of all news releases and financials visit Alpha Pro Tech's
Website at http://www.alphaprotech.com.
Contacts:
Alpha Pro Tech, Ltd.
Al Millar or Donna Millar, 905-479-0654
ir@alphaprotech.com
or
Hayden Communications, Inc.
Matthew Hayden, 843-272-4653 (Investor Relations)
matt@haydenir.com
Brett Maas, 843-272-4653 (Investor Relations)